This study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and VARILRIX™ [Oka-RIT strain SmithKline Beecham Biologicals] in healthy children 12-24 months of age. Subjects were randomized in this double blind study to receive either a single dose of Oka/Merck varicella vaccine, (∼50,000 plaque forming units (PFU), Group A or ∼16,000PFU, Group B) or 1 dose of VARILRIX™, (∼40,000PFU/dose, Group C). Safety profiles in each treatment group were similar. The proportions of subjects achieving a 6-week postvaccination titer ≥5 gpELISA units in Groups A, B or C were 97.1, 95.2 and 85.6%, respectively.
- Varicella vaccination
- Varicella zoster virus
ASJC Scopus subject areas
- Molecular Medicine
- Immunology and Microbiology(all)
- Public Health, Environmental and Occupational Health
- Infectious Diseases